Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients
Clinical trial NCT02693171 · TERMINATED
Trial details
- NCT number
- NCT02693171
- Sponsor
- United Therapeutics
- Status
- TERMINATED
- Study type
- OBSERVATIONAL
- Start date
- 2016-03-15
- Primary completion
- 2016-12-19
- Enrollment
- 13
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.